ES2224122T3 - Inmunoterapia de cancer con linfocitos alogenicos. - Google Patents

Inmunoterapia de cancer con linfocitos alogenicos.

Info

Publication number: ES2224122T3
Authority: ES; Spain
Prior art keywords: patient; cells; day; days; lymphocytes
Prior art date: 1994-03-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

ES95913730T

Other languages

English (en)

Spanish (es)

Inventor

Shimon Slavin

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-03-17

Filing date

1995-03-16

Publication date

2005-03-01

1995-03-16 Application filed by Individual filed Critical Individual

2005-03-01 Application granted granted Critical

2005-03-01 Publication of ES2224122T3 publication Critical patent/ES2224122T3/es

2015-03-16 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

210000004698 lymphocyte Anatomy 0.000 title claims description 102
238000002619 cancer immunotherapy Methods 0.000 title 1
210000004027 cell Anatomy 0.000 claims abstract description 243
238000000034 method Methods 0.000 claims abstract description 46
206010028980 Neoplasm Diseases 0.000 claims abstract description 38
201000011510 cancer Diseases 0.000 claims abstract description 17
230000000735 allogeneic effect Effects 0.000 claims description 112
238000011282 treatment Methods 0.000 claims description 100
210000001744 T-lymphocyte Anatomy 0.000 claims description 66
201000010099 disease Diseases 0.000 claims description 44
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 44
230000003211 malignant effect Effects 0.000 claims description 37
210000000130 stem cell Anatomy 0.000 claims description 37
230000000694 effects Effects 0.000 claims description 35
229940126530 T cell activator Drugs 0.000 claims description 29
208000032839 leukemia Diseases 0.000 claims description 28
230000009467 reduction Effects 0.000 claims description 25
239000003814 drug Substances 0.000 claims description 16
206010025323 Lymphomas Diseases 0.000 claims description 13
239000012190 activator Substances 0.000 claims description 9
206010006187 Breast cancer Diseases 0.000 claims description 8
208000026310 Breast neoplasm Diseases 0.000 claims description 8
230000011132 hemopoiesis Effects 0.000 claims description 7
206010061819 Disease recurrence Diseases 0.000 claims description 6
230000036755 cellular response Effects 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 5
229940079593 drug Drugs 0.000 claims description 4
230000019491 signal transduction Effects 0.000 claims description 4
102000013462 Interleukin-12 Human genes 0.000 claims description 3
108010065805 Interleukin-12 Proteins 0.000 claims description 3
108010047620 Phytohemagglutinins Proteins 0.000 claims description 3
108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 3
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 3
230000001885 phytohemagglutinin Effects 0.000 claims description 3
108010062580 Concanavalin A Proteins 0.000 claims description 2
102000003816 Interleukin-13 Human genes 0.000 claims description 2
108090000176 Interleukin-13 Proteins 0.000 claims description 2
150000002148 esters Chemical class 0.000 claims description 2
230000036210 malignancy Effects 0.000 claims 2
230000003247 decreasing effect Effects 0.000 claims 1
230000036961 partial effect Effects 0.000 abstract description 19
238000000338 in vitro Methods 0.000 abstract description 17
230000004913 activation Effects 0.000 abstract description 11
230000008030 elimination Effects 0.000 abstract description 11
238000003379 elimination reaction Methods 0.000 abstract description 11
238000011084 recovery Methods 0.000 abstract description 6
210000005105 peripheral blood lymphocyte Anatomy 0.000 abstract description 5
230000007170 pathology Effects 0.000 abstract 1
241000699670 Mus sp. Species 0.000 description 70
238000001727 in vivo Methods 0.000 description 49
210000001185 bone marrow Anatomy 0.000 description 47
108020003175 receptors Proteins 0.000 description 46
102000005962 receptors Human genes 0.000 description 46
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 38
238000010254 subcutaneous injection Methods 0.000 description 35
239000007929 subcutaneous injection Substances 0.000 description 35
230000003750 conditioning effect Effects 0.000 description 33
210000004989 spleen cell Anatomy 0.000 description 31
238000002591 computed tomography Methods 0.000 description 30
208000009329 Graft vs Host Disease Diseases 0.000 description 26
201000001779 Leukocyte adhesion deficiency Diseases 0.000 description 26
210000002798 bone marrow cell Anatomy 0.000 description 26
208000024908 graft versus host disease Diseases 0.000 description 26
238000001802 infusion Methods 0.000 description 24
210000005259 peripheral blood Anatomy 0.000 description 22
239000011886 peripheral blood Substances 0.000 description 22
230000004044 response Effects 0.000 description 22
229960001924 melphalan Drugs 0.000 description 21
SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 21
FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 18
238000002474 experimental method Methods 0.000 description 17
210000001165 lymph node Anatomy 0.000 description 16
229960001196 thiotepa Drugs 0.000 description 16
210000004881 tumor cell Anatomy 0.000 description 15
101150045189 cmo gene Proteins 0.000 description 14
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 14
229960005420 etoposide Drugs 0.000 description 14
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 13
238000009169 immunotherapy Methods 0.000 description 13
101150054032 lspA gene Proteins 0.000 description 13
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 12
210000004369 blood Anatomy 0.000 description 12
239000008280 blood Substances 0.000 description 12
238000002512 chemotherapy Methods 0.000 description 12
238000012546 transfer Methods 0.000 description 12
239000012636 effector Substances 0.000 description 11
210000000952 spleen Anatomy 0.000 description 11
230000001684 chronic effect Effects 0.000 description 10
210000000265 leukocyte Anatomy 0.000 description 10
230000001404 mediated effect Effects 0.000 description 10
239000000203 mixture Substances 0.000 description 10
238000012544 monitoring process Methods 0.000 description 10
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 9
208000010833 Chronic myeloid leukaemia Diseases 0.000 description 9
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 9
229960004397 cyclophosphamide Drugs 0.000 description 9
230000036571 hydration Effects 0.000 description 9
238000006703 hydration reaction Methods 0.000 description 9
208000031261 Acute myeloid leukaemia Diseases 0.000 description 8
206010055113 Breast cancer metastatic Diseases 0.000 description 8
231100000518 lethal Toxicity 0.000 description 8
230000001665 lethal effect Effects 0.000 description 8
WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 7
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 7
102000004127 Cytokines Human genes 0.000 description 7
108090000695 Cytokines Proteins 0.000 description 7
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 7
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 7
208000007660 Residual Neoplasm Diseases 0.000 description 7
OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 7
229960002092 busulfan Drugs 0.000 description 7
190000008236 carboplatin Chemical compound 0.000 description 7
229960004562 carboplatin Drugs 0.000 description 7
229940047766 co-trimoxazole Drugs 0.000 description 7
230000006698 induction Effects 0.000 description 7
108010002350 Interleukin-2 Proteins 0.000 description 6
102000000588 Interleukin-2 Human genes 0.000 description 6
206010027476 Metastases Diseases 0.000 description 6
230000001154 acute effect Effects 0.000 description 6
210000000601 blood cell Anatomy 0.000 description 6
238000002659 cell therapy Methods 0.000 description 6
230000008029 eradication Effects 0.000 description 6
230000003394 haemopoietic effect Effects 0.000 description 6
230000001965 increasing effect Effects 0.000 description 6
238000002347 injection Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
238000003752 polymerase chain reaction Methods 0.000 description 6
230000002829 reductive effect Effects 0.000 description 6
238000007920 subcutaneous administration Methods 0.000 description 6
206010002961 Aplasia Diseases 0.000 description 5
241000282412 Homo Species 0.000 description 5
230000009286 beneficial effect Effects 0.000 description 5
239000010836 blood and blood product Substances 0.000 description 5
238000004820 blood count Methods 0.000 description 5
229940125691 blood product Drugs 0.000 description 5
239000000463 material Substances 0.000 description 5
238000001959 radiotherapy Methods 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
238000002054 transplantation Methods 0.000 description 5
101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 description 4
101000642464 Homo sapiens Spermatogenesis-associated protein 2-like protein Proteins 0.000 description 4
102000004889 Interleukin-6 Human genes 0.000 description 4
108090001005 Interleukin-6 Proteins 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
102100030254 Spermatogenesis-associated protein 2 Human genes 0.000 description 4
230000000719 anti-leukaemic effect Effects 0.000 description 4
230000008901 benefit Effects 0.000 description 4
238000010322 bone marrow transplantation Methods 0.000 description 4
230000001143 conditioned effect Effects 0.000 description 4
230000036039 immunity Effects 0.000 description 4
229960003444 immunosuppressant agent Drugs 0.000 description 4
239000003018 immunosuppressive agent Substances 0.000 description 4
239000002054 inoculum Substances 0.000 description 4
IFWCCHXFUMLVAF-WEZQJLTASA-N n-[(4r,4as,7ar,12br)-9-hydroxy-3-methyl-7-oxo-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-4a-yl]-2-sulfanylacetamide Chemical compound O([C@H]1C(CC[C@]23NC(=O)CS)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O IFWCCHXFUMLVAF-WEZQJLTASA-N 0.000 description 4
230000003836 peripheral circulation Effects 0.000 description 4
238000011321 prophylaxis Methods 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
208000017604 Hodgkin disease Diseases 0.000 description 3
208000017605 Hodgkin disease nodular sclerosis Diseases 0.000 description 3
208000010747 Hodgkins lymphoma Diseases 0.000 description 3
102000000704 Interleukin-7 Human genes 0.000 description 3
108010002586 Interleukin-7 Proteins 0.000 description 3
241000700159 Rattus Species 0.000 description 3
239000000427 antigen Substances 0.000 description 3
108091007433 antigens Proteins 0.000 description 3
102000036639 antigens Human genes 0.000 description 3
210000003719 b-lymphocyte Anatomy 0.000 description 3
239000011324 bead Substances 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
230000003021 clonogenic effect Effects 0.000 description 3
229940100601 interleukin-6 Drugs 0.000 description 3
229940100994 interleukin-7 Drugs 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
238000004599 local-density approximation Methods 0.000 description 3
239000002609 medium Substances 0.000 description 3
206010061289 metastatic neoplasm Diseases 0.000 description 3
210000004214 philadelphia chromosome Anatomy 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
230000008569 process Effects 0.000 description 3
238000010926 purge Methods 0.000 description 3
230000005855 radiation Effects 0.000 description 3
238000011946 reduction process Methods 0.000 description 3
239000000523 sample Substances 0.000 description 3
230000001052 transient effect Effects 0.000 description 3
230000005945 translocation Effects 0.000 description 3
210000003462 vein Anatomy 0.000 description 3
PBUUPFTVAPUWDE-UGZDLDLSSA-N 2-[[(2S,4S)-2-[bis(2-chloroethyl)amino]-2-oxo-1,3,2lambda5-oxazaphosphinan-4-yl]sulfanyl]ethanesulfonic acid Chemical compound OS(=O)(=O)CCS[C@H]1CCO[P@](=O)(N(CCCl)CCCl)N1 PBUUPFTVAPUWDE-UGZDLDLSSA-N 0.000 description 2
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
102000001554 Hemoglobins Human genes 0.000 description 2
108010054147 Hemoglobins Proteins 0.000 description 2
101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 2
102000008070 Interferon-gamma Human genes 0.000 description 2
108010074328 Interferon-gamma Proteins 0.000 description 2
102000000589 Interleukin-1 Human genes 0.000 description 2
108010002352 Interleukin-1 Proteins 0.000 description 2
102000004388 Interleukin-4 Human genes 0.000 description 2
108090000978 Interleukin-4 Proteins 0.000 description 2
102000000743 Interleukin-5 Human genes 0.000 description 2
108010002616 Interleukin-5 Proteins 0.000 description 2
206010025280 Lymphocytosis Diseases 0.000 description 2
206010027452 Metastases to bone Diseases 0.000 description 2
206010027457 Metastases to liver Diseases 0.000 description 2
241001529936 Murinae Species 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
238000010171 animal model Methods 0.000 description 2
230000000259 anti-tumor effect Effects 0.000 description 2
238000002617 apheresis Methods 0.000 description 2
238000009395 breeding Methods 0.000 description 2
230000001488 breeding effect Effects 0.000 description 2
210000004970 cd4 cell Anatomy 0.000 description 2
239000002771 cell marker Substances 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
229910052804 chromium Inorganic materials 0.000 description 2
239000011651 chromium Substances 0.000 description 2
210000000349 chromosome Anatomy 0.000 description 2
230000002559 cytogenic effect Effects 0.000 description 2
231100000135 cytotoxicity Toxicity 0.000 description 2
230000003013 cytotoxicity Effects 0.000 description 2
230000007423 decrease Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
238000002224 dissection Methods 0.000 description 2
239000012634 fragment Substances 0.000 description 2
102000055277 human IL2 Human genes 0.000 description 2
238000002649 immunization Methods 0.000 description 2
230000003053 immunization Effects 0.000 description 2
230000001861 immunosuppressant effect Effects 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
238000011081 inoculation Methods 0.000 description 2
230000003993 interaction Effects 0.000 description 2
229960003130 interferon gamma Drugs 0.000 description 2
229940117681 interleukin-12 Drugs 0.000 description 2
229940028885 interleukin-4 Drugs 0.000 description 2
229940100602 interleukin-5 Drugs 0.000 description 2
231100000636 lethal dose Toxicity 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
230000007774 longterm Effects 0.000 description 2
239000008176 lyophilized powder Substances 0.000 description 2
229950000547 mafosfamide Drugs 0.000 description 2
KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
229960001156 mitoxantrone Drugs 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
239000000843 powder Substances 0.000 description 2
230000002265 prevention Effects 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
239000007787 solid Substances 0.000 description 2
210000000278 spinal cord Anatomy 0.000 description 2
230000002269 spontaneous effect Effects 0.000 description 2
238000012360 testing method Methods 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
230000035899 viability Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
RNAMYOYQYRYFQY-UHFFFAOYSA-N 2-(4,4-difluoropiperidin-1-yl)-6-methoxy-n-(1-propan-2-ylpiperidin-4-yl)-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine Chemical compound N1=C(N2CCC(F)(F)CC2)N=C2C=C(OCCCN3CCCC3)C(OC)=CC2=C1NC1CCN(C(C)C)CC1 RNAMYOYQYRYFQY-UHFFFAOYSA-N 0.000 description 1
206010000830 Acute leukaemia Diseases 0.000 description 1
208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
208000004736 B-Cell Leukemia Diseases 0.000 description 1
206010065553 Bone marrow failure Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
241000222120 Candida <Saccharomycetales> Species 0.000 description 1
235000006481 Colocasia esculenta Nutrition 0.000 description 1
240000004270 Colocasia esculenta var. antiquorum Species 0.000 description 1
229930105110 Cyclosporin A Natural products 0.000 description 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
108010036949 Cyclosporine Proteins 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
101001043807 Homo sapiens Interleukin-7 Proteins 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
101150083678 IL2 gene Proteins 0.000 description 1
206010062016 Immunosuppression Diseases 0.000 description 1
108010078049 Interferon alpha-2 Proteins 0.000 description 1
108010047761 Interferon-alpha Proteins 0.000 description 1
102000006992 Interferon-alpha Human genes 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
206010064912 Malignant transformation Diseases 0.000 description 1
208000034486 Multi-organ failure Diseases 0.000 description 1
102000043276 Oncogene Human genes 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
238000010222 PCR analysis Methods 0.000 description 1
206010033661 Pancytopenia Diseases 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
102100023606 Retinoic acid receptor alpha Human genes 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
206010041660 Splenomegaly Diseases 0.000 description 1
108700025695 Suppressor Genes Proteins 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
210000002593 Y chromosome Anatomy 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
208000024340 acute graft versus host disease Diseases 0.000 description 1
208000026784 acute myeloblastic leukemia with maturation Diseases 0.000 description 1
230000002411 adverse Effects 0.000 description 1
108700025316 aldesleukin Proteins 0.000 description 1
208000033571 alveolar capillary dysplasia with misalignment of pulmonary veins Diseases 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000013459 approach Methods 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
230000036765 blood level Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
238000000423 cell based assay Methods 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000006037 cell lysis Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
208000017760 chronic graft versus host disease Diseases 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
238000005138 cryopreservation Methods 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
239000003651 drinking water Substances 0.000 description 1
235000020188 drinking water Nutrition 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
210000003754 fetus Anatomy 0.000 description 1
230000003325 follicular Effects 0.000 description 1
PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 1
230000006870 function Effects 0.000 description 1
230000005714 functional activity Effects 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
230000012010 growth Effects 0.000 description 1
230000002489 hematologic effect Effects 0.000 description 1
210000003958 hematopoietic stem cell Anatomy 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
230000007236 host immunity Effects 0.000 description 1
102000052622 human IL7 Human genes 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
230000001024 immunotherapeutic effect Effects 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000009399 inbreeding Methods 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
230000002101 lytic effect Effects 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000036212 malign transformation Effects 0.000 description 1
239000003550 marker Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000002483 medication Methods 0.000 description 1
239000003147 molecular marker Substances 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
210000000214 mouth Anatomy 0.000 description 1
208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
229940053050 neomycin sulfate Drugs 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
210000004940 nucleus Anatomy 0.000 description 1
208000004594 persistent fetal circulation syndrome Diseases 0.000 description 1
210000004180 plasmocyte Anatomy 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
230000002028 premature Effects 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
208000037821 progressive disease Diseases 0.000 description 1
229940087463 proleukin Drugs 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
238000011127 radiochemotherapy Methods 0.000 description 1
208000037922 refractory disease Diseases 0.000 description 1
230000003307 reticuloendothelial effect Effects 0.000 description 1
108091008726 retinoic acid receptors α Proteins 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
238000004088 simulation Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
238000000528 statistical test Methods 0.000 description 1
238000011476 stem cell transplantation Methods 0.000 description 1
210000001562 sternum Anatomy 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
230000001629 suppression Effects 0.000 description 1
230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
210000002303 tibia Anatomy 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
230000026683 transduction Effects 0.000 description 1
238000010361 transduction Methods 0.000 description 1
239000000439 tumor marker Substances 0.000 description 1
210000003954 umbilical cord Anatomy 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/204—IL-6
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2046—IL-7
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/22—Immunosuppressive or immunotolerising
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/418—Antigens related to induction of tolerance to non-self
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Microbiology (AREA)
Cell Biology (AREA)
Hematology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

ES95913730T 1994-03-17 1995-03-16 Inmunoterapia de cancer con linfocitos alogenicos. Expired - Lifetime ES2224122T3 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US21494494A	1994-03-17	1994-03-17
US214944		1994-03-17

Publications (1)

Publication Number	Publication Date
ES2224122T3 true ES2224122T3 (es)	2005-03-01

Family

ID=22801017

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES95913730T Expired - Lifetime ES2224122T3 (es)	1994-03-17	1995-03-16	Inmunoterapia de cancer con linfocitos alogenicos.

Country Status (9)

Country	Link
US (3)	US5843435A (2)
EP (1)	EP0750505B1 (2)
JP (1)	JPH09510456A (2)
AU (1)	AU2100695A (2)
CA (1)	CA2184352A1 (2)
DE (1)	DE69533189T2 (2)
ES (1)	ES2224122T3 (2)
IL (1)	IL112969A (2)
WO (1)	WO1995024910A1 (2)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL112969A (en) *	1994-03-17	2001-05-20	Baxter Int	Pharmaceutical compositions for the treatment of cancer comprising allogenic lymphocytes or their combination with a t-cell activator
AU5930396A (en) *	1995-05-25	1996-12-11	Baxter International Inc.	Allogeneic cell therapy for cancer following allogeneic stem cell transplantation
US5800539A (en) *	1995-11-08	1998-09-01	Emory University	Method of allogeneic hematopoietic stem cell transplantation without graft failure or graft vs. host disease
ES2203782T3 (es) *	1996-01-17	2004-04-16	Imperial College Innovations Limited	Inmunoterapia que utiliza linfocitos t citotoxicos (ctl).
US6213127B1 (en)	1996-07-29	2001-04-10	Emory University	Methods for treating cancer using allogeneic lymphocytes without graft vs host disease activity
US5834487A (en) *	1996-09-24	1998-11-10	Cv Therapeutics	Inhibition of 26S and 20S proteasome by indanones
EP1011694A4 (en) *	1996-11-15	2000-11-15	Baxter Int	TREATMENT FOR ALLOGENIC STEM CELL TRANSPLANTATION
US6428782B1 (en) *	1997-05-23	2002-08-06	Hadasit Medical Research Services And Development Ltd.	Non-myeloablative tolerogenic treatment
AU9589398A (en) *	1997-10-10	1999-05-03	Applied Immunotherapeutics, Inc.	Cancer immunotherapy using allostimulated cells in a multiple sequential implantation strategy
US20040033230A1 (en) *	1997-12-24	2004-02-19	Corixa Corporation	Compositions and methods for the therapy and diagnosis of breast cancer
US6969518B2 (en) *	1998-12-28	2005-11-29	Corixa Corporation	Compositions and methods for the therapy and diagnosis of breast cancer
US7598226B2 (en)	1998-12-28	2009-10-06	Corixa Corporation	Compositions and methods for the therapy and diagnosis of breast cancer
WO2001040269A2 (en) *	1999-11-30	2001-06-07	Corixa Corporation	Compositions and methods for therapy and diagnosis of breast cancer
US7541184B2 (en)	2000-02-24	2009-06-02	Invitrogen Corporation	Activation and expansion of cells
US7572631B2 (en)	2000-02-24	2009-08-11	Invitrogen Corporation	Activation and expansion of T cells
JP4917201B2 (ja) *	2000-12-04	2012-04-18	株式会社リンフォテック	臍帯血移植後の腫瘍および各種感染症の予防・治療用製剤、臍帯血移植後の移植臍帯血幹細胞の生着促進用製剤、臍帯血移植後の腫瘍および各種感染症の予防・治療用製剤ならびに臍帯血移植後の移植臍帯血幹細胞の生着促進用製剤の製造方法。
KR20020060643A (ko) *	2002-06-04	2002-07-18	김진경	타인의 면역시스템을 이용하는 암의 치료 방법
US20050084967A1 (en)	2002-06-28	2005-04-21	Xcyte Therapies, Inc.	Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
US20040175373A1 (en) *	2002-06-28	2004-09-09	Xcyte Therapies, Inc.	Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
WO2004003142A2 (en) *	2002-06-28	2004-01-08	Xcyte Therapies, Inc.	Compositions and methods for restoring immune repertoire in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
WO2005021734A2 (en) *	2003-09-02	2005-03-10	University Of Massachussets	Generation of hematopoietic chimerism and induction of central tolerance
EP1713441A2 (en) *	2004-02-12	2006-10-25	Nektar Therapeutics	Interleukin-13 antagonist powders, spray-dried particles, and methods
EP1755685A4 (en) *	2004-05-28	2008-11-12	Mayo Foundation	METHODS FOR TRANSPLANTATION OF AUTOLOGOUS STEM CELLS
US9155789B2 (en) *	2005-04-25	2015-10-13	New York University	Use of allogenic or syngenic major histocompatibility complex (MHC) molecules as universal adjuvants for vaccines against neoplastic disease, infection and autoimmune disease
EP2054444B1 (en)	2006-08-04	2016-11-02	MedImmune Limited	Antibodies to erbb2
PL2068874T3 (pl)	2006-08-07	2015-06-30	Abbvie Biotherapeutics Inc	Sposoby leczenia szpiczaka mnogiego z użyciem terapii skojarzonych opartych na przeciwciałach anty-cs1
JP2010500370A (ja)	2006-08-07	2010-01-07	ピーディーエルバイオファーマ，インコーポレイティド	多発性硬化症を処置するための抗ｃｓ１抗体を用いる組成物および方法
EP2089042A2 (en) *	2006-11-08	2009-08-19	Aldagen, Inc.	Methods for improved engraftment following stem cell transplantation
CA2668608A1 (en) *	2006-11-08	2008-06-05	Aldagen, Inc.	Methods for using aldhbr cells to supplement stem cell transplantation
KR20120054018A (ko) *	2009-08-17	2012-05-29	도꾜 다이가꾸	일과성 생착 ｃｔｌ을 포함하는 의약품 조성물
MX370404B (es) *	2011-12-22	2019-12-11	Yeda Res & Dev	Uso de una terapia de combinación para inducir un injerto estable y a largo plazo.
US10365280B2 (en)	2014-10-02	2019-07-30	Dana-Farber Cancer Institute, Inc.	Compositions and methods for treating malignancies
US10302644B2 (en)	2014-11-04	2019-05-28	Dana-Farber Cancer Institute, Inc.	Compositions and methods for treating multiple myeloma
EP3595683A1 (en)	2017-03-15	2020-01-22	Orca Biosystems, Inc.	Compositions and methods for hematopoietic stem cell transplants
US12594341B2 (en)	2020-06-14	2026-04-07	Shimon Slavin	Multifunctional immunotherapeutic monoclonal antibody complexes and conjugates

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4690915A (en) *	1985-08-08	1987-09-01	The United States Of America As Represented By The Department Of Health And Human Services	Adoptive immunotherapy as a treatment modality in humans
US4861589A (en) *	1987-03-23	1989-08-29	Trustees Of Boston University	Method for therapeutically treating abnormal cells expressing a major histocompatibility complex class II antigen using cytolytic inducer T4 cells
US5126132A (en) *	1989-08-21	1992-06-30	The United States Of America As Represented By The Department Of Health And Human Services	Tumor infiltrating lymphocytes as a treatment modality for human cancer
JPH07102131B2 (ja) *	1991-07-15	1995-11-08	日本石油株式会社	ヒトリンパ球の癌細胞に対する傷害活性を高める方法
IL112969A (en) *	1994-03-17	2001-05-20	Baxter Int	Pharmaceutical compositions for the treatment of cancer comprising allogenic lymphocytes or their combination with a t-cell activator

1995
- 1995-03-13 IL IL11296995A patent/IL112969A/en not_active IP Right Cessation
- 1995-03-16 ES ES95913730T patent/ES2224122T3/es not_active Expired - Lifetime
- 1995-03-16 DE DE69533189T patent/DE69533189T2/de not_active Expired - Lifetime
- 1995-03-16 WO PCT/US1995/003303 patent/WO1995024910A1/en not_active Ceased
- 1995-03-16 EP EP95913730A patent/EP0750505B1/en not_active Expired - Lifetime
- 1995-03-16 US US08/714,144 patent/US5843435A/en not_active Expired - Lifetime
- 1995-03-16 AU AU21006/95A patent/AU2100695A/en not_active Abandoned
- 1995-03-16 CA CA002184352A patent/CA2184352A1/en not_active Abandoned
- 1995-03-16 JP JP7524180A patent/JPH09510456A/ja active Pending
1996
- 1996-10-23 US US08/735,496 patent/US5928639A/en not_active Expired - Lifetime
2001
- 2001-12-03 US US10/005,747 patent/US20020176850A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP0750505A1 (en)	1997-01-02
CA2184352A1 (en)	1995-09-21
DE69533189T2 (de)	2005-07-21
US20020176850A1 (en)	2002-11-28
JPH09510456A (ja)	1997-10-21
IL112969A0 (en)	1995-06-29
US5928639A (en)	1999-07-27
WO1995024910A1 (en)	1995-09-21
IL112969A (en)	2001-05-20
AU2100695A (en)	1995-10-03
EP0750505B1 (en)	2004-06-23
DE69533189D1 (de)	2004-07-29
MX9604099A (es)	1997-09-30
US5843435A (en)	1998-12-01

Publication	Publication Date	Title
ES2224122T3 (es)	2005-03-01	Inmunoterapia de cancer con linfocitos alogenicos.
Mizui	2019	Natural and modified IL-2 for the treatment of cancer and autoimmune diseases
EP0831860B1 (en)	2004-10-20	Allogeneic cell therapy for cancer following allogeneic stem cell transplantation
US6544787B1 (en)	2003-04-08	Non-myeloablative/lymphoablative conditioning regimen to induce patient anti-donor unresponsiveness in stem cell transplantation
Rossi et al.	2019	Immune precision medicine for cancer: a novel insight based on the efficiency of immune effector cells
Rosenberg et al.	1989	Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients
Rosenberg	1991	Immunotherapy and gene therapy of cancer
ES2855475T3 (es)	2021-09-23	Expansión de linfocitos con una composición de citocinas para inmunoterapia celular activa
CN102271702B (zh)	2015-11-25	抗第三方中枢记忆性t细胞、产生其的方法及其在移植和疾病治疗中的用途
IL257678B1 (en)	2023-12-01	Methods for stem cell transplantation
O’Neal et al.	2024	Traversing the bench to bedside journey for iNKT cell therapies
Okita et al.	2009	Targeting of CD4+ CD25high cells while preserving CD4+ CD25low cells with low-dose chimeric anti-CD25 antibody in adoptive immunotherapy of cancer
US6447767B1 (en)	2002-09-10	Non-myeloablative tolerogenic treatment
WO2020102226A1 (en)	2020-05-22	Combination therapies for multiple myeloma
EP3440196A1 (en)	2019-02-13	Method for preparing lymphocytes capable of infiltrating a solid tumor, lymphocytes obtainable by said method and uses thereof
JP2002520262A (ja)	2002-07-09	Ｔリンパ球交換
US20230355678A1 (en)	2023-11-09	Methods for improving t cell efficacy
EA015510B1 (ru)	2011-08-30	Способ увеличения количества мононуклеарных клеток у субъекта, страдающего раком, и используемая для этого фармацевтическая комбинация
Swan	2023	Enhancing Chimeric Antigen Receptor T cell therapy in Mouse EGFRvIII Heterogeneous Glioblastoma
Song et al.	2020	Donor gdT Cells Promote GVL Effect and Mitigate aGVHD in Allogeneic Hematopoietic Stem Cell Transplantation
MXPA96004099A (en)	1998-07-03	Immunotherapy of cancer with lymphocytes alogeni
Ghanta et al.	2000	Immunotherapy of a murine T cell lymphoma localized to the brain
Hashino et al.	1996	Antileukemic Effects of Interleukin 2 after Allogeneic Bone Marrow Transplantation in AKR/J Mice
Fewkes et al.	2012	Modulation of immune cell niches for therapeutics in cancer and inflammatory diseases
MXPA99004444A (en)	2000-07-01	Conditioning for allogeneic stem cell transplantation